Sunshine Biopharma, Inc. (SBFM)

Market Cap	4.36M
Revenue (ttm)	32.96M
Net Income (ttm)	-4.23M
Shares Out	2.00M
EPS (ttm)	-26.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,728
Open	2.290
Previous Close	2.280
Day's Range	2.180 - 2.336
52-Week Range	2.180 - 638.000
Beta	-1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2024

About SBFM

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: SBFM
• Website: https://sunshinebiopharma.com

Financial Performance

In 2023, Sunshine Biopharma's revenue was $24.09 million, an increase of 454.42% compared to the previous year's $4.35 million. Losses were -$4.51 million, -83.15% less than in 2022.